长春高新：子公司三价流感病毒裂解疫苗临床试验申请获得批准

Core Viewpoint - Changchun High-tech announced that its subsidiary, Baike Biotech, received the Clinical Trial Approval Notice from the National Medical Products Administration for its trivalent influenza virus split vaccine, allowing clinical trials to prevent influenza caused by related strains of the virus [1] Group 1 - The vaccine is targeted at individuals aged 60 and above [1] - The vaccine utilizes a split virus technology route and is combined with a self-developed adjuvant to ensure safety while enhancing immunogenicity [1] - Successful completion of clinical trials and subsequent approval for market launch will further enhance the company's influenza vaccine research pipeline and expand its coverage among the population [1]